Studying How Children's Bodies Process Energy and Muscle During Brain Tumor Treatment
Measures metabolism and muscle in children with brain tumors, before and after treatment.
Plain-language title generated from the registry record
Registry title: Whole Body Metabolism in Children Before and After Treatment of CNS Tumor
Key facts
- Where
- Copenhagen, DenmarkSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 6 and 18 years old?
Source: NCT06380387, who can take part
Where in Denmark
- Department of Pediatrics and Adolescent Medicine and Copenhagen Neuromuscular Center, RigshospitaletCopenhagen, DenmarkTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Copenhagen University Hospital, Rigshospitalet
- Trial code
- NCT06380387
- Record updated
- 23 April 2024
- Original description
At the center of pediatric oncology in Copenhagen the investigators experience that the children with brain tumor, more or less have a healthy body with normal skeletal muscle mass and are physical active to the same level as their friends at the same age. The treatment period for brain tumor is approximately two years. After the treatment period, the children are more sedative with less interest in coming out doing physical activities and thus the investigators suspect that they have altered hormonal response, low skeletal muscle mass and perhaps are in risk of developing metabolic syndrome.Read full original descriptionShow less
Whole Body Metabolism in Children Before and After Treatment of CNS Tumor
At the center of pediatric oncology in Copenhagen the investigators experience that the children with brain tumor, more or less have a healthy body with normal skeletal muscle mass and are physical active to the same level as their friends at the same age. The treatment period for brain tumor is approximately two years. After the treatment period, the children are more sedative with less interest in coming out doing physical activities and thus the investigators suspect that they have altered hormonal response, low skeletal muscle mass and perhaps are in risk of developing metabolic syndrome.
By comparing children with newly diagnosed CNS tumor with children finished treated for CNS tumor, we wish to describe the metabolic path during the approximately two years treatment period these children go through. These results will also be compared with results from healthy controls.
The investigators aim to include 10 children (aged 6-18 years) with newly diagnosed CNS tumor, 10 children (aged 6-18 years) finished treated for CNS tumor and 10 healthy controls (aged 6-18 years). By using stable isotope technique the investigators will investigate systemic fat, glucose and protein metabolism together with liver protein degradation and glucose production. Furthermore, by using DXA scan the investigators will describe the quality and distribution of skeletal muscle. Lastly, the investigators will determine the skeletal muscle signal pathway and metabolism in skeletal muscle via the Bergström biopsy technique in vastus lateralis.
Inclusion: Patient group A: Children with newly diagnosed CNS tumor, included just before the start of treatment or right after possible surgery; Patient group B: Children who have completed treatment for a CNS tumor within the last month; Healthy controls: Children admitted to the EMU because of either; Suspected convulsions; Nocturnal EEG changes; 6-18 years; Signed informed consent to participation in the trial.
Exclusion: Intake of medications that may interfere with the results, evaluated by investigator; Competing conditions at risk of compromising the results of the study; Inability to understand the purpose of the trial or cooperate in the conduction of the experiments. For the children this will concern of course the parents or the guardians of the child; Participation in other trials that may interfere with the results; Pregnancy or breastfeeding.